Hassan Waseem, Abdelwahab Siddig Ibrahim, Farasani Abdullah, Moshi Jobran M, Alshahrani Saeed
Institute of Chemical Sciences, University of Peshawar, Peshawar, Khyber Pakhtunkhwa, 25120, Pakistan.
Health Research Center, Jazan University, Jazan, Saudi Arabia.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 3. doi: 10.1007/s00210-025-04199-4.
Naunyn-Schmiedeberg's Archives of Pharmacology has been a prominent journal in pharmacology since its inception in 1873, contributing significantly to experimental and clinical pharmacology, as well as toxicology. Despite its origins as the official journal of the German Society of Experimental and Clinical Pharmacology and Toxicology, there is a commonly held assumption that it predominantly publishes research from Germany. This study challenges that notion by examining the journal's publication dynamics over time, including the historical output, international participation, and regional contributions. The analysis of 25,931 documents indexed from 1873 to 2025 reveals a significant increase in global engagement, with contributions from 104 countries. While Germany remained the leading contributor until 2020, a decline in its share of publications is observed, with countries like China, India, and Iran surpassing Germany in recent years. The study demonstrates the journal's growing international influence and its evolution into a globally recognized platform for pharmacological research. In parallel with its increasing international reach, the journal has distinguished itself through an active commitment to academic integrity and ethical publishing. Initiatives such as post-publication image reviews, retractions of fraudulent articles, and mandatory AI disclosure policies reflect its proactive stance against scientific misconduct. Furthermore, its support for gender equity and historical accountability-evident in studies on editorial diversity, and award disparities-underscores its role as a pharmacological journal with a conscience. Together, these findings highlight both the geographic diversification and ethical leadership of a journal shaping pharmacological science on a global scale.
自1873年创刊以来，《瑙尼恩-施米德贝格药理学文献》一直是药理学领域的著名期刊，对实验药理学、临床药理学以及毒理学都做出了重大贡献。尽管它起源于德国实验与临床药理学及毒理学协会的官方期刊，但人们普遍认为它主要发表来自德国的研究。本研究通过考察该期刊随时间推移的出版动态，包括历史产出、国际参与情况和地区贡献，对这一观点提出了挑战。对1873年至2025年索引的25931篇文献的分析显示，全球参与度显著提高，有来自104个国家的贡献。虽然直到2020年德国一直是主要贡献国，但近年来其发表份额有所下降，中国、印度和伊朗等国家已超过德国。该研究表明该期刊的国际影响力不断增强，已发展成为一个全球公认的药理学研究平台。随着其国际影响力的不断扩大，该期刊通过积极致力于学术诚信和道德出版而脱颖而出。诸如发表后图像审查、撤稿欺诈性文章以及强制人工智能披露政策等举措，反映了其对科研不端行为的积极立场。此外，它对性别平等和历史责任的支持——在编辑多样性和奖项差异研究中显而易见——凸显了其作为一本有良知的药理学期刊的作用。这些发现共同凸显了一本在全球范围内塑造药理学科学的期刊的地域多元化和道德引领作用。
